GLUE - monterosatx.com Trailing Twelve Months Revenue Growth

Monte Rosa Therapeutics (GLUE) is actively implementing an innovative targeted protein degradation system, leveraging a major partnership with a global pharma leader to fund its research. Platform monetization is secured by long-term patents and payments from industry behemoths. Revenues are based on the commercialization of "molecular glues" to combat oncology. The LTM annual change in sales volume visualizes revenue dynamics, while the -61.30 metric confirms the current level.

Monte Rosa Therapeutics - GLUE Sales Growth YoY (TTM) (period 02/11/2024 - 11/15/2026)

Monte Rosa Therapeutics, Inc. - analytical breakdowns and key metrics (GLUE)

- price and consensus price forecast:

Price Rate Chart Monte Rosa Tx|GLUE - Analyst Consensus Forecast

- market capitalization statistics:

Market Value Monte Rosa Tx|GLUE - Real Price to Acquire Entire Company

- book capitalization data:

Book Price of a Share Monte Rosa Therapeutics|GLUE - Book Capitalization|Market-to-Book Ratio monterosatx.com|GLUE - Company Total Assets

- company total debt and liquidity indicators:

Debt to Equity Ratio Monte Rosa Therapeutics|GLUE - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Monte Rosa Tx|GLUE - Company Total Debt|Debt to Book Capital Monte Rosa Therapeutics, Inc.|GLUE - Company Long-Term Debts|Company Short-Term Loans and Borrowings Monte Rosa Therapeutics|Immediate Liquidity monterosatx.com

- financial results and valuation multiples details:

GLUE - Company Net Income|Expected Net Income Monte Rosa Therapeutics|GLUE - P/E Multiple|Forward P/E Multiple monterosatx.com|GLUE - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Monte Rosa Tx|GLUE - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Monte Rosa Therapeutics|GLUE - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months monterosatx.com|GLUE - Earnings per share growth in current year|Expected net earnings per share growth next year Monte Rosa Therapeutics

- sales revenue and business income indicators:

GLUE - Company Revenue|Company Revenue Forecast Monte Rosa Therapeutics|GLUE - Market Cap to Revenue|Price to Expected Revenue Ratio Monte Rosa Therapeutics, Inc.|GLUE - Sales Growth YoY (TTM)

Fundamental company valuation:Monte Rosa Tx GLUE

Monte Rosa Therapeutics (GLUE) holds a strong position in developing innovative protein degradation methods for cancer therapy. Analyzing the TTM revenue growth dynamics, an investor sees a smoothed trajectory of operational efficiency, where the upward trend confirms management quality, yet signals a risk of overvaluation of the asset at the peak of the current breakthrough technology development cycle.

Who Monte Rosa Therapeutics competes with

Revenue Growth Rate YoY (Last Twelve Months) Genmab US|Exelixis Inc - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvalent|KYMR (Kymera Therapeutics) - Revenue Growth YoY (Last 12 Months)|IDYA: Revenue Change YoY (Last 12 Months)|ELVN (enliventherapeutics.com) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth ORIC Pharma ORIC|Sales Growth YoY (TTM) RLAY|Nurix Therapeutics, Inc. - Sales Growth YoY (Last 12 Months)|Tyra Biosciences - Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) VSTM|CGEM: Revenue Growth YoY (Last 12 Months)|Immuneering Inc. - Revenue Change YoY (Last 12 Months)|CCCC: Sales Growth YoY (TTM)|Black Diamond - Revenue Dynamics YoY (Last Twelve Months)|RPTX (Repare Therapeutics Inc) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth PMV Pharmaceuticals Inc. PMVP|Sales Growth YoY (Last Twelve Months) Karyopharm Therapeutics, Inc. (KPTI)|PPCB (Propanc Biopharma) - Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BGMS (Cyclacel)|Sales Growth YoY (TTM) Aadi Bioscience AADI|ALRN - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Sales Growth BPMC|GLYC (glycomimetics.com) - Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth SpringWorks Therapeutics, Inc (SWTX)